Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on June 11, 2007

Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hym031
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/5/337    most recent
hym031v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tanimoto, K.
Right arrow Articles by Tobinai, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanimoto, K.
Right arrow Articles by Tobinai, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 Foundation for Promotion of Cancer Research

Primary Ocular Adnexal MALT Lymphoma: A Long-term Follow-up Study of 114 Patients

Kazuki Tanimoto1, Akihiro Kaneko2, Shigenobu Suzuki2, Naohiro Sekiguchi1, Takashi Watanabe1, Yukio Kobayashi1, Yoshikazu Kagami3, Akiko Miyagi Maeshima4, Yoshihiro Matsuno4 and Kensei Tobinai1,

1 Hematology and Stem Cell Transplantation Division
2 Ophthalmology Division
3 Radiation Oncology Division
4 Pathology Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan

For reprints and all correspondence: Kensei Tobinai, Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: ktobinai{at}ncc.go.jp

Received October 14, 2006; accepted January 17, 2007

Background: Although primary ocular adnexal MALT (mucosa-associated lymphoid tissue ) lymphoma (POAML) is a recently recognized unique entity, its natural history, prognostic factors, behavior of progression and death, and standard initial management have not been fully elucidated.

Methods: The data of 114 patients with histologically verified POAML who were treated at our institution between 1970 and 2003 were retrospectively analyzed.

Results: With a median follow-up duration of 5.7 years (0.6–34.0), estimated overall survival (OS) rate and progression-free survival (PFS) rate at 10 years was 89% and 57%, respectively. Thirteen (11%) patients died, but only three (3%) of them due to progressive lymphoma. Thirty-one (27%) patients progressed: eight who progressed at contra lateral sites were limited to those who had initially involved in the orbit (P = 0.036) and their OS and PFS were significantly longer (P = 0.035 and 0.039, respectively). Patients who initially received radiation-containing therapy were superior in PFS but not in OS to those initially treated with other modalities (P = 0.016 and 0.091, respectively). When we compared the outcomes of the observation cohort and the immediate therapy cohort, there were no significant differences in OS and PFS (P = 0.499 and 0.073, respectively).

Conclusions: The majority of patients with POAML showed the behaviors of localized and indolent diseases. Our preliminary observation that no initial therapy is an acceptable approach for selected patients was confirmed. Considering the possible heterogeneity of POAML among initial sites, further investigations are warranted.

Key Words: MALT lymphoma • heterogeneity • observation • retrospective study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. Stefanovic and I. S. Lossos
Extranodal marginal zone lymphoma of the ocular adnexa
Blood, July 16, 2009; 114(3): 501 - 510.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
L. D. Sjo, S. Heegaard, J. U. Prause, B. L. Petersen, S. Pedersen, and E. Ralfkiaer
Extranodal Marginal Zone Lymphoma in the Ocular Region: Clinical, Immunophenotypical, and Cytogenetical Characteristics
Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 516 - 522.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.